Change in the number of shares and votes in Camurus

Lund — 30 December 2015 — Camurus AB (publ) (NASDAQ STO:CAMX) today announced
that the company’s total number of shares as per 30 December 2015 amounts to
37,281,486 shares, corresponding to an equal number of votes. The increase in
the number of shares and votes results from the three new share issues of in
total 12,072,926 shares which were carried out in connection with the listing of
the company’s share on Nasdaq Stockholm on 3 December 2015.

About Camurus

Camurus is a Swedish research-based pharmaceutical company committed to
developing and commercialising innovative and differentiated medicines for the
treatment of severe and chronic conditions. New drug products with best-in-class
potential are conceived based on the proprietary FluidCrystal® drug delivery
technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes
products for treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international pharmaceutical
companies. The company’s shares are listed on Nasdaq Stockholm under the ticker
“CAMX”. For more information, visit www.camurus.com.

For more information
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
ir@camurus.com

The information in this press release is disclosed by Camurus AB in accordance
with the Swedish Securities Markets Act and/or the Swedish Financial Instruments
Trading Act. The information was submitted for publication at 07.00 a.m. on 30
December 2015.